Dulaglutide Injection - Diabetes (recombinant Route)， Weight Loss/diabetes Bulk and Pre-filled Pen 0.75mg : 0.5ml, 1.5mg : 0.5ml, CAS No.: 923950-08-7

Introduction

As a manufacturer located in China, we offer a range of quality products for merchants in countries outside China. One of our most popular products is the Dulaglutide Injection for Diabetes and Weight Loss. This product is available in both bulk and pre-filled pen versions, with varying concentrations of the active ingredient.

Dulaglutide is a recombinant protein that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs are designed to lower blood glucose levels by stimulating the body's production of insulin and reducing the production of glucagon, a hormone that raises blood glucose levels.

The Dulaglutide injection is approved for the treatment of type II diabetes mellitus, and has also been shown to promote weight loss in some patients. In this article, we will explore the various aspects of this product that make it an attractive option for merchants looking to stock high-quality diabetic medications.

Efficacy

The efficacy of the Dulaglutide injection has been well-established through numerous clinical trials. In a study published in the New England Journal of Medicine, patients who received Dulaglutide had a greater reduction in HbA1c levels (a measure of blood glucose over time) compared to those who received a placebo.

Patients who received Dulaglutide also experienced greater reductions in body weight, blood pressure, and cholesterol levels compared to the placebo group. These improvements were observed even in patients who had difficulty achieving glycemic control with other medications.

Additionally, the pre-filled pen version of the Dulaglutide injection has been shown to be more convenient and easier to use than traditional syringes. This can improve patient adherence and contribute to better glycemic control over time.

Safety

Safety is a critical concern when it comes to diabetic medications, and it is an area in which the Dulaglutide injection excels. The drug has a well-established safety profile, with few serious adverse events reported in clinical trials.

The most common side effects of Dulaglutide include nausea, vomiting, and diarrhea, although these typically resolve within a few days. Severe hypoglycemia, a potential complication of many diabetes medications, is rare with Dulaglutide.

Another advantage of the Dulaglutide injection is its long-lasting effect. The pre-filled pen version of the drug can be taken once weekly, which can reduce the risk of hypoglycemia caused by missed doses.

Competitive Pricing

As a manufacturer, we understand that pricing is a critical factor for merchants looking to stock their shelves with high-quality products. We are proud to offer the Dulaglutide injection at a highly competitive price point, without sacrificing quality.

Our bulk and pre-filled pen versions of the Dulaglutide injection come in multiple concentrations, allowing merchants to choose the option that best fits their customer's needs. We also offer volume discounts and special promotions to help our merchant partners maintain a healthy bottom line.

Market Potential

The market potential for diabetic medications is vast, with an estimated 463 million people worldwide living with diabetes. This makes it one of the largest chronic disease markets in the world, with significant growth potential in the coming years.

In addition, the market for weight loss medications is also growing rapidly, as more people become aware of the link between obesity and chronic disease. The Dulaglutide injection is well-positioned to capitalize on both of these markets, making it an attractive option for merchants looking to expand their product lines.

Conclusion

In summary, the Dulaglutide injection is an excellent option for merchants looking to stock high-quality diabetic medications in their stores. Its proven efficacy, excellent safety profile, and competitive pricing make it an attractive option for both patients and merchants alike.

As a manufacturer based in China, we are proud to offer this product to merchants worldwide, and we are committed to delivering the highest quality products to our customers. If you are interested in learning more about the Dulaglutide injection or any of our other products, please do not hesitate to contact us today.

DESCRIPTION

Dulaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell (Chinese hamster ovary) culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37). Structural modifications were introduced in the GLP-1 part of the molecule responsible for interaction with the enzyme dipeptidyl-peptidase-IV (DPP-4). Additional modifications were made in an area with a potential T-cell epitope and in the areas of the IgG4 Fc part of the molecule responsible for binding the high-affinity Fc receptors and half-antibody formation. The overall molecular weight of dulaglutide is approximately 63 kilodaltons.

DULAGLUTIDE (dulaglutide) injection is a clear, colorless, sterile, preservative-free solution for subcutaneous use. Each single-dose pen contains a 0.5 mL solution of 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg of dulaglutide and the following excipients: citric acid anhydrous (0.07 mg), mannitol (23.2 mg), polysorbate 80 (0.10 mg for 0.75 mg and 1.5 mg; 0.125 mg for 3 mg and 4.5 mg), and trisodium citrate dihydrate (1.37 mg), in water for injection.

Mechanism of Action

DULAGLUTIDE contains dulaglutide, which is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.

Pharmacodynamics

DULAGLUTIDE lowers fasting glucose and reduces postprandial glucose (PPG) concentrations in patients with type 2 diabetes mellitus. The reduction in fasting and postprandial glucose can be observed after a single dose.

Fasting and Postprandial Glucose In a clinical pharmacology study in patients with type 2 diabetes mellitus, treatment with once weekly DULAGLUTIDE resulted in a reduction of fasting and 2-hour PPG concentrations, and postprandial serum glucose incremental AUC, when compared to placebo (-25.6 mg/dL, -59.5 mg/dL, and -197 mg*h/dL, respectively); these effects were sustained after 6 weeks of dosing with the 1.5 mg dose. First- and Second-Phase Insulin Secretion Both first- and second-phase insulin secretion were increased in patients with type 2 diabetes treated with DULAGLUTIDE compared with placebo. Insulin and Glucagon Secretion DULAGLUTIDE stimulates glucose-dependent insulin secretion and reduces glucagon secretion. Treatment with DULAGLUTIDE 0.75 mg and 1.5 mg once weekly increased fasting insulin from baseline at Week 26 by 35.38 and 17.50 pmol/L, respectively, and C-peptide concentration by 0.09 and 0.07 nmol/L, respectively, in a monotherapy trial. In the same trial, fasting glucagon concentration was reduced by 1.71 and 2.05 pmol/L from baseline with DULAGLUTIDE 0.75 mg and 1.5 mg, respectively. Gastric Motility Dulaglutide causes a delay of gastric emptying. The delay in gastric emptying is dose-dependent but is attenuated with adequate dose escalation to higher doses of DULAGLUTIDE. The delay is largest after the first dose and diminishes with subsequent doses. Cardiac Electrophysiology (QTc) The effect of dulaglutide on cardiac repolarization was tested in a thorough QTc study. Dulaglutide did not produce QTc prolongation at doses of 4 and 7 mg. The maximum recommended dose is 4.5 mg once weekly.

Name: Dulaglutide

DULAGLUTIDE contains dulaglutide, a human GLP-1 receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37). Structural modifications were introduced in the GLP-1 part of the molecule responsible for interaction with the enzyme dipeptidyl-peptidase-IV (DPP-4). Additional modifications were made in an area with a potential T-cell epitope and in the areas of the IgG4 Fc part of the molecule responsible for binding the high-affinity Fc receptors and half-antibody formation. The overall molecular weight of dulaglutide is approximately 63 kilodaltons.

Dosage: Injection

Specification

0.75mg: 0.5ml, 1.5mg : 0.5ml,

Indications

DULAGLUTIDE is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

In 2020, the company's R&D center and some production lines settled in Hangzhou Pharmaceutical Town, and the level of R&D and production of software and hardware has been effectively improved. With the help of academician expert workstations, post-doctoral workstations and other scientific research platforms, Jiuyuan vigorously develops the research and development of macromolecular drugs focusing on insulin and monoclonal antibodies.

Based on the product positioning of innovative drugs and generic drugs, and both biological drugs and chemical drugs, the company focuses on the development of new drugs in the fields of tumor, blood, cardiovascular, hepatitis, diabetes, etc.

The company has successively won many honorary titles such as National High-tech Enterprise, National Torch Program Key High-tech Enterprise, Provincial Science and Technology Progress Second Prize, Provincial Famous Trademark, Provincial High-tech Research and Development Center, etc.

Company Honor

National New High-tech Enterprise

Key New High-tech Enterprise of National Torch Plan

National superior enterprise of intellectual property

Provincial New High-tech Research & Development Center

Zhejiang Provincial Enterprise Technology Center

Zhejiang Famous Trademark

Zhejiang Jiuyuan Gene Engineering Biopharmaceutical Research Institute

FAQ

Q: Are you trading company or manufacturer?

A: We are professional manufacturer specialized in the research, development, manufacture and marketing of pharmaceuticals based on gene engineering and biochemical technology since 1993.

And we trade our products with our clients directly.

Q: How many different types of products your company manufactures?

A: Now we have 36 products including pipeline products. All the pharmaceutical manufacturing activities are carried as per GMP requirements. The day to day licensing and regulatory activities are controlled by SFDA.

Q: When can I get the price?

A: Usually we quote within 8 hours after we get your inquiry.

Q: What's your MOQ?

A: If we have the products in stock, it will be no MOQ. If we need to produce, we can discuss the MOQ according to customer's exact situation.

Q: How long is your delivery time?

A: The general delivery time is 30-45 days after receiving your order confirmation. if we have the goods in stock, it will only take 1-2 days.

Our Services

1. Good knowledge on different market can meet special requirements.

2. Real manufacturer with our own factory located in china.

3. Strong professional technical team ensure to produce the top quality products.

4. Special cost control system ensure to provide the most favorable price.

5. Rich experience on drug.

Why choose us?

• We are a trusted manufacturer of Recombinant Diabetes Injection products and provide excellent service.
• We have a mature process and modern management mode, and are committed to the development of Dulaglutide Injection - Diabetes (recombinant Route)， Weight Loss/diabetes Bulk and Pre-filled Pen 0.75mg : 0.5ml, 1.5mg : 0.5ml, CAS No.: 923950-08-7 market. We continue to improve professional services to meet various needs of customers.
• Our company is a leading manufacturer of Recombinant Diabetes Injection products in China, and we offer the best prices.
• We are in an era of rapid change, constantly contributing to the achievement of a sustainable society on the one hand, and accelerating our strategic transformation towards new growth on the other.
• We are a leading manufacturer of Recombinant Diabetes Injection products in China, and we offer competitive pricing.
• With the development of the market, our company constantly strive to focus on the Dulaglutide Injection - Diabetes (recombinant Route)， Weight Loss/diabetes Bulk and Pre-filled Pen 0.75mg : 0.5ml, 1.5mg : 0.5ml, CAS No.: 923950-08-7 itself while using modern management.
• Our Chinese factory produces top-quality Recombinant Diabetes Injection products at unbeatable prices.
• For specific problems at work, employees have the right to make appropriate decisions according to their own understanding, provided that they do not violate the work plan and work principles. Employees are not passive executors, but workers who are allowed a degree of autonomy and decision-making power.
• We are suppliers of Recombinant Diabetes Injection products and also a leading manufacturer in China.
• We use quality and credibility to open up the market, rich varieties to meet customer needs, and continuous reform to improve customer satisfaction.

Hot Tags: dulaglutide injection - diabetes (recombinant route)， weight loss/diabetes bulk and pre-filled pen 0.75mg : 0.5ml, 1.5mg : 0.5ml, cas no.: 923950-08-7, China dulaglutide injection - diabetes (recombinant route)， weight loss/diabetes bulk and pre-filled pen 0.75mg : 0.5ml, 1.5mg : 0.5ml, cas no.: 923950-08-7 manufacturers, suppliers, factory, diabetes management quality, diabetes management distributor, diabetic treatment application field, diabetic control usage, injection for diabetes export, Semaglutide injection pre-filled pen